NTRA vs VCYT
NTRA: Natera uses proprietary blood-based cell-free DNA technology to deliver personalized genetic diagnostics for oncology, prenatal screening, and organ transplant health. VCYT: Veracyte is a genomics-focused diagnostics company providing high-value clinical tests to improve cancer detection and treatment guidance for patients worldwide.
Side-by-side fundamentals
| Metric | NTRA | VCYT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $264.22 | $58.01 | |
| Market cap as of 2026-07-23 | $37.9B | $4.8B | |
| P/E as of 2026-07-23 | n/a | 53.97 | |
| PEG as of 2026-07-23 | -13.63 | 0.34 | NTRA lower |
| Net margin as of 2026-07-23 | -9.1% | +16.3% | VCYT higher |
| Gross margin as of 2026-07-23 | +65.1% | +70.9% | VCYT higher |
| Operating margin as of 2026-07-23 | -13.0% | +15.1% | VCYT higher |
| ROE as of 2026-07-23 | -15.1% | +6.9% | VCYT higher |
| ROA as of 2026-07-23 | -10.5% | +6.3% | VCYT higher |
| Debt / equity as of 2026-07-23 | 0.05 | 0.00 | VCYT lower |
| Revenue growth (YoY) as of 2026-07-23 | +36.6% | +16.9% | NTRA higher |
| Revenue CAGR (3y) SEC XBRL | +41.1% | +20.4% | NTRA higher |
| Beta as of 2026-07-23 | 1.54 | 1.94 | |
| 1-year return as of 2026-07-22 close | +88.8% | +146.7% | VCYT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.